19F MRI for quantitative in vivo cell tracking

Trends in Biotechnology

Volumn 28, Issue 7, 2010, Pages 363-370

  Srinivas, Mangala ^a   Heerschap, Arend ^a   Ahrens, Eric T ^b   Figdor, Carl G ^a   de Vries, I Jolanda M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LABELING; CELL TRACKING; CELLULAR THERAPEUTICS; CELLULAR THERAPY; CLINICAL APPLICATION; CLINICAL USE; CONTRAST AGENT; DENDRITIC CELLS; DIRECT DETECTION; IMAGING MODALITY; IMAGING TECHNOLOGY; IN-VIVO; LABELED CELLS; NON-INVASIVE IMAGING; STEM CELL;

DENDRIMERS; RESONANCE; STEM CELLS;

MAGNETIC RESONANCE IMAGING;

CONTRAST MEDIUM; FLUORINE;

BIOTECHNOLOGY; CELL; CELL COUNT; CELL LABELING; CELL THERAPY; CELL TRACKING; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN; IN VIVO STUDY; INTRACELLULAR SPACE; PRIORITY JOURNAL; REVIEW;

CELL MOVEMENT; CONTRAST MEDIA; FLUORINE; FLUOROCARBONS; HUMANS; MAGNETIC RESONANCE IMAGING; TISSUE THERAPY; WHOLE BODY IMAGING;

EID: 77953898938     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2010.04.002     Document Type: Review

References (74)

1. Lucignani G., et al. Molecular imaging of cell-mediated cancer immunotherapy. Trends Biotechnol. 2006, 24:410-418.
2. de Vries I.J., et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 2005, 23:1407-1413.
3. Bulte J.W. In vivo MRI cell tracking: clinical studies. Am. J. Roentgenol. 2009, 193:314-325. http://www.ncbi.nlm.nih.gov/pubmed/19620426.
4. Himmelreich U., Dresselaers T. Cell labeling and tracking for experimental models using magnetic resonance imaging. Methods 2009, 48:112-124.
5. Gilad A.A., et al. Developing MR reporter genes: promises and pitfalls. NMR Biomed. 2007, 20:275-290.
6. Calamante F., et al. Contrast agent concentration measurements affecting quantification of bolus-tracking perfusion MRI. Magn. Reson. Med. 2007, 58:544-553.
7. Liu W., Frank J.A. Detection and quantification of magnetically labeled cells by cellular MRI. Eur. J. Radiol. 2009, 70:258-264.
8. Arbab A.S., et al. Cellular magnetic resonance imaging: current status and future prospects. Expert Rev. Med. Devices 2006, 3:427-439.
9. Goulle J.P., et al. MRI gadolinium-based contrast agents. Radiologists beware!. Ann. Pharm. Fr. 2009, 67:335-339.
10. Nelson T.R., et al. Fluorine nuclear magnetic resonance: calibration and system optimization. Magn. Reson. Imaging 1985, 3:267-273.
11. Holland G.N., et al. 19F magnetic resonance imaging. J. Magn. Res. 1977, 28:133-136.
12. Tran T.D., et al. Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int. J. Nanomed. 2007, 2:515-526. http://www.ncbi.nlm.nih.gov/pubmed/18203420.
13. Simberg D., Mattrey R. Targeting of perfluorocarbon microbubbles to selective populations of circulating blood cells. J. Drug Target. 2009, 17:392-398.
14. Rapoport N., et al. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl. Cancer Inst. 2007, 99:1095-1106.
15. Diaz-Lopez R., et al. Liquid perfluorocarbons as contrast agents for ultrasonography and (19)F-MRI. Pharm. Res. 2010, 27:1-16.
16. Moriyasu F., Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. Am. J. Roentgenol. 2009, 193:86-95. PMID: 19542399.
17. Soman N., Banerjee R. Artificial vitreous replacements. Biomed. Mater. Eng. 2003, 13:59-74.
18. Lanza G.M., et al. 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. Curr. Top. Dev. Biol. 2005, 70:57-76.
19. Lanza G.M., et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002, 106:2842-2847.
20. Noth U., et al. 19F-MRI in vivo determination of the partial oxygen pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues. Magn. Reson. Med. 1999, 42:1039-1047.
21. Thomas S.R., et al. Perfluorocarbon compound aerosols for delivery to the lung as potential 19F magnetic resonance reporters of regional pulmonary pO2. Invest. Radiol. 1997, 32:29-38.
22. Langereis S., et al. A temperature-sensitive liposomal 1H CEST and 19F contrast agent for MR image-guided drug delivery. J. Am. Chem. Soc. 2009, 131:1380-1381.
23. Mancini L., et al. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy. NMR Biomed. 2009, 22:561-566.
24. Yu J., et al. Synthesis and evaluation of a novel gene reporter molecule: detection of beta-galactosidase activity using 19F NMR of a fluorinated vitamin B6 conjugate+. Med. Chem. 2005, 1:255-262.
25. Flogel U., et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008, 118:140-148.
26. Kaneda M.M., et al. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann. Biomed. Eng. 2009, 37:1922-1933. PMID: 19184435.
27. Moore A., et al. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes 2004, 53:1459-1466.
28. Morawski A.M., et al. Quantitative 'magnetic resonance immunohistochemistry' with ligand-targeted (19)F nanoparticles. Magn. Reson. Med. 2004, 52:1255-1262.
29. Shapiro E.M., et al. Magnetic resonance imaging of the migration of neuronal precursors generated in the adult rodent brain. Neuroimage 2006, 32:1150-1157.
30. Arbab A.S., et al. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 2003, 76:1123-1130.
31. Arbab A.S., et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004, 104:1217-1223.
32. Walczak P., et al. Instant MR labeling of stem cells using magnetoelectroporation. Magn. Reson. Med. 2005, 54:769-774.
33. Zhao M., et al. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 2002, 13:840-844.
34. Ahrens E.T., et al. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn. Reson. Med. 2003, 49:1006-1013.
35. Bulte J.W., et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat. Biotechnol. 2001, 19:1141-1147.
36. Ahrens E.T., et al. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotechnol. 2005, 23:983-987.
37. Srinivas M., et al. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn. Reson. Med. 2007, 58:725-734.
38. Ruiz-Cabello J., et al. In vivo 'hot spot' MR imaging of neural stem cells using fluorinated nanoparticles. Magn. Reson. Med. 2008, 60:1506-1511.
39. Srinivas M., et al. In vivo cytometry of antigen-specific t cells using (19)F MRI. Magn. Reson. Med. 2009, 62:749-753. http://www.ncbi.nlm.nih.gov/pubmed/19585593.
40. Janjic J.M., et al. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J. Am. Chem. Soc. 2008, 130:2832-2841.
41. Helfer B.M., et al. Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy 2010, 12:238-250. PMID: 20053146.
42. Verdijk P., et al. Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int. J. Cancer 2007, 120:978-984.
43. Mistretta C.A. Undersampled radial MR acquisition and highly constrained back projection (HYPR) reconstruction: potential medical imaging applications in the post-Nyquist era. J. Magn. Reson. Imaging 2009, 29:501-516.
44. Bornert P., et al. Fast perfluorocarbon imaging using 19F U-FLARE. Magn. Reson. Med. 1993, 29:226-234.
45. Gowland P.A., De Wilde J. Temperature increase in the fetus due to radio frequency exposure during magnetic resonance scanning. Phys. Med. Biol. 2008, 53:L15-L18.
46. Jager L.J., et al. Half-life of perfluorooctylbromide in inner organs determined by fast 19F-NMR imaging. Adv. Exp. Med. Biol. 1994, 361:129-134.
47. Noth U., et al. Fast 19F-NMR imaging in vivo using FLASH-MRI. Magn. Reson. Imaging 1994, 12:149-153.
48. Noth U., et al. In vivo measurement of partial oxygen pressure in large vessels and in the reticuloendothelial system using fast 19F-MRI. Magn. Reson. Med. 1995, 34:738-745.
49. Weigel M., et al. Inversion recovery prepared turbo spin echo sequences with reduced SAR using smooth transitions between pseudo steady states. Magn. Reson. Med. 2007, 57:631-637.
50. Ahrens E.T., et al. Magnetic resonance imaging of embryonic and fetal development in model systems. Methods Mol. Med. 2006, 124:87-101.
51. Barber B.J., et al. Thermal effects of MR imaging: worst-case studies on sheep. Am. J. Roentgenol. 1990, 155:1105-1110. PMID: 2120944.
52. Partlow K.C., et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007, 21:1647-1654.
53. Waters E.A., et al. Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy. Magn. Reson. Med. 2008, 60:1232-1236.
54. Mattrey R.F. The potential role of perfluorochemicals (PFCs) in diagnostic imaging. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994, 22:295-313.
55. De Wilde J.P., et al. A review of the current use of magnetic resonance imaging in pregnancy and safety implications for the fetus. Prog. Biophys. Mol. Biol. 2005, 87:335-353.
56. Tsai L.L., et al. An open-access, very-low-field MRI system for posture-dependent 3He human lung imaging. J. Magn. Reson. 2008, 193:274-285.
57. Kurhanewicz J., et al. Current and potential applications of clinical 13C MR spectroscopy. J. Nucl. Med. 2008, 49:341-344.
58. Viale A., Aime S. Current concepts on hyperpolarized molecules in MRI. Curr. Opin. Chem. Biol. 2010, 14:90-96.
59. Flaim S.F. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994, 22:1043-1054.
60. Millard R.W. Oxygen solubility, rheology and hemodynamics of perfluorocarbon emulsion blood substitutes. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994, 22:235-244.
61. Zarif L., et al. Biodistribution and excretion of a mixed fluorocarbon-hydrocarbon 'dowel' emulsion as determined by 19F NMR. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994, 22:1193-1198.
62. Olsen G.W., et al. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod. Toxicol. 2009, 27:212-230.
63. Natalin R.A., et al. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J. Urol. 2010, 183:27-33.
64. Geraldes C.F., Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol. Imaging 2009, 4:1-23.
65. Lee H.K., et al. Correction for chemical-shift artifacts in 19F imaging of PFOB: simultaneous multislice imaging. Magn. Reson. Med. 1991, 21:21-29.
66. Lee H.K., et al. Correction of chemical-shift artifacts in 19F imaging of PFOB: a robust signed magnitude method. Magn. Reson. Med. 1992, 23:254-263.
67. Yu J.X., et al. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr. Med. Chem. 2005, 12:819-848.
68. Peng H., et al. Synthesis and evaluation of partly fluorinated block copolymers as MRI imaging agents. Biomacromolecules 2009, 10:374-381.
69. Kodibagkar V.D., et al. Physical principles of quantitative nuclear magnetic resonance oximetry. Front. Biosci. 2008, 13:1371-1384.
70. Neubauer A.M., et al. Gadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn. Reson. Med. 2008, 60:1066-1072.
71. Krylova O.O., Pohl P. Ionophoric activity of pluronic block copolymers. Biochemistry 2004, 43:3696-3703.
72. Grindel J.M., et al. Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J. Pharm. Sci. 2002, 91:1936-1947.
73. Yoon J.K., Burgess D.J. Interfacial properties as stability predictors of lecithin-stabilized perfluorocarbon emulsions. Pharm. Dev. Technol. 1996, 1:333-341.
74. Criscione J.M., et al. Self-assembly of pH-responsive fluorinated dendrimer-based particulates for drug delivery and noninvasive imaging. Biomaterials 2009, 30:3946-3955.